NCT04629755 is a NA clinical trial of Intervention in Depression, sponsored by University of Washington.

Who is sponsoring NCT04629755?

NCT04629755 is sponsored by University of Washington.

What drugs are being tested in NCT04629755?

Interventions in NCT04629755: Intervention.

What condition does NCT04629755 study?

NCT04629755 studies Depression, Loneliness, Relation, Interpersonal, Covid19.

Is NCT04629755 still recruiting?

NCT04629755 is currently completed. Last updated 19 November 2020.

Last reviewed 2020-11-19 · How we verify

NCT04629755

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Smartphone Intervention for Relational and Mental Well Being

Completed NA Last updated 19 November 2020

What this trial tests

NA trial testing Intervention in Depression in 1,765 participants. Completed in 3 August 2020.

Timeline

4 April 2020

Primary endpoint
3 August 2020

3 August 2020

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	1,765
Start date	4 April 2020
Primary completion	3 August 2020
Estimated completion	3 August 2020
Sites	1 location across United States

Drugs / interventions tested

Intervention

Conditions studied

Depression — all drugs for Depression →
Loneliness — all drugs for Loneliness →
Relation, Interpersonal — all drugs for Relation, Interpersonal →
Covid19 — all drugs for Covid19 →

Sponsor

University of Washington

Who can join

18 and older, any sex, with Depression or Loneliness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this study is to provide and evaluate a phone-based intervention to improve relational and mental well-being during the COVID-19 crisis. This information also will help us understand how individuals are responding to COVID-19 and have the potential to inform psychological and policy level interventions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

COVID 19 pandemic challenges and their management: A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues.
Mohapatra S, Ayash Kumar P, Farooq U, Jain P, et al · · 2022 · cited 3× · PMID 35645588 · DOI 10.1016/j.jsps.2022.05.004

Verify or expand the search:

Other trials of Intervention

Trials testing the same drug.

NCT07038317 — A Text Messaging Trial to Test Vaping Health Messages Optimized to Young Adults' Vaping Status · NA · not yet recruiting
NCT06112431 — Eye Health Intervention Study in Upper Manhattan · NA · not yet recruiting
NCT07202390 — Intraarticular Gold Microparticles for Knee Osteoarthritis · NA · not yet recruiting
NCT07444736 — Effect of 8 Weeks of Resistance Training With Blood Flow Restriction on Muscle Strength, Clinical Parameters, Biochemica · NA · enrolling by invitation
NCT07376668 — Effects of a WhatsApp-assisted Prehabilitation for Patient Undergoing Elective Colorectal Cancer Surgery · NA · not yet recruiting

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04629755 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 19 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04629755.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing